A randomized comparison of a dual therapy stent - which combines low-dose sirolimus delivery from an abluminal biodegradable polymer matrix with a covalently bound anti-CD34 antibody layer - with a paclitaxel-eluting stent showed that the dual therapy stent effectively controls neointimal...